Mid Cap Pharma Stocks

The table below shows Mid Cap Pharma Stocks based on the Highest Market Capitalization.

Content:

• What are Mid Cap Pharma Stocks?
• Best Mid Cap Pharma Stocks
• Top Mid Cap Pharma Stocks
• List Of Best Mid Cap Pharma Stocks
• Best Mid Cap Pharma Stocks
• Who Should Invest In Mid Cap Pharma Stocks?
• How To Invest In The Mid Cap Pharma Stocks?
• Performance Metrics Of Mid Cap Pharma Stocks
• Benefits Of Investing In Mid Cap Pharma Stocks
• Challenges Of Investing In Mid Cap Pharma Stocks
• Introduction to Mid Cap Pharma Stocks
• Best Mid Cap Pharma Stocks – FAQs

What are Mid Cap Pharma Stocks?

Mid cap pharma stocks represent pharmaceutical companies with medium-sized market capitalizations, typically between $2 billion and $10 billion. These companies often balance the rapid growth potential of small cap companies with the stability of large caps, making them attractive to investors seeking moderate risk and growth.

These companies may already have approved products in the market, generating steady revenue streams while still investing in new drug development. This blend allows for both stability in earnings and potential for expansion, which can attract a broader base of institutional investors.

Additionally, mid cap pharma stocks usually have better funding for research and development compared to their smaller counterparts. This funding enables more sustained drug pipeline development, which is critical for long-term success in the pharmaceutical industry, potentially leading to significant stock appreciation with successful drug launches.

Best Mid Cap Pharma Stocks

The table below shows Best Mid Cap Pharma Stocks based on 1 Year Return.

Top Mid Cap Pharma Stocks

The table below shows Top Mid Cap Pharma Stocks based on 1 Month Return.

List Of Best Mid Cap Pharma Stocks

The table below shows a List Of Best Mid Cap Pharma Stocks based on the highest day Volume.

Best Mid Cap Pharma Stocks

The table below shows the Best Mid Cap Pharma Stocks based on the PE Ratio.

Who Should Invest In Mid Cap Pharma Stocks?

Investors seeking a balance between risk and growth potential should consider investing in mid cap pharma stocks. These stocks offer exposure to companies with established products and promising pipelines, suitable for those looking to diversify their portfolio with potentially stable yet growth-oriented investments.

Investors in mid cap pharma stocks can benefit from the companies’ potential to innovate and expand, without the extreme volatility often associated with smaller companies. This makes them a safer bet for those wary of the speculative nature of small caps but desiring more growth than large caps typically offer.

However, these stocks still carry risks associated with clinical trials and regulatory approvals. Investors should have a moderate risk tolerance and be prepared for possible fluctuations driven by product success or failure in the market. This level of investment suits those who can commit to staying informed on sector developments.

How To Invest In The Mid Cap Pharma Stocks?

To invest in mid cap pharma stocks, start by opening an account with Alice Blue. Utilize their research tools to analyze the financial stability, drug pipeline potential, and market position of various mid-cap pharmaceutical companies, ensuring they align with your investment goals.

Focus on companies that show consistent revenue growth and have a promising pipeline of drugs that are in late-stage clinical trials. These factors are critical indicators of potential success and can significantly impact the stock’s future performance. Use Alice Blue’s insights to assess these aspects thoroughly.

Maintain a diversified portfolio by investing in several mid cap pharma stocks to mitigate risks associated with individual companies’ failures. Regularly review your investments to adapt to changes in the market environment and the regulatory landscape, which can swiftly affect pharmaceutical stocks.

Performance Metrics Of Mid Cap Pharma Stocks

Performance metrics of mid cap pharma stocks include revenue growth, earnings per share (EPS), return on equity (ROE), and the progress of drug pipelines. These indicators help assess a company’s financial health and its potential for future growth, crucial for making informed investment decisions.

Revenue growth is a key metric, showing how effectively a company is expanding its sales and market presence. This metric is especially important in the pharma industry, where growth can indicate successful market penetration and adoption of new drugs.

EPS and ROE provide insights into a company’s profitability and financial efficiency. A rising EPS suggests improving profitability, while a strong ROE indicates efficient use of equity. Both are important for evaluating a company’s capability to generate returns relative to its capital.

Benefits Of Investing In Mid Cap Pharma Stocks

The main benefits of investing in mid cap pharma stocks include a balanced risk-return profile. These companies offer growth potential from innovative drug pipelines and financial stability from existing product lines, making them attractive to investors seeking growth with relatively lower volatility than small cap stocks.

• Balanced Growth Opportunity: Mid-cap pharma stocks provide a sweet spot between the high growth potential of small caps and the stability of large caps. They often have enough resources to fund significant research and development, which can lead to breakthroughs and substantial financial gains.

• Lower Volatility: While offering growth potential, mid cap pharma stocks typically exhibit less volatility compared to their small-cap counterparts. This reduced volatility stems from having more established products in the market, which can provide more predictable revenue streams.

• Innovation with Stability: Mid cap companies frequently manage to maintain innovation while achieving financial stability. They are large enough to invest in substantial R&D efforts but agile enough to adapt quickly to market changes, striking an optimal balance for many investors.

• Attractive Acquisition Targets: Mid cap pharma firms are often prime candidates for acquisitions by larger pharmaceutical companies looking to expand their product lines. Such acquisitions can significantly increase the stock value, benefiting shareholders.

Challenges Of Investing In Mid Cap Pharma Stocks

The main challenges of investing in mid cap pharma stocks include regulatory risks, dependency on successful drug development, and market competition. These factors can lead to significant stock volatility, requiring investors to have a comprehensive understanding of the sector and individual company prospects to manage potential risks effectively.

• Regulatory Hurdles: Mid cap pharma stocks often face stringent regulatory challenges. Navigating FDA approvals can be uncertain and time-consuming, directly impacting stock performance based on trial outcomes or regulatory feedback, which can either catapult a stock upward or lead to substantial declines.

• Development Dependency: These companies heavily rely on the successful development and market acceptance of new drugs. Failure in clinical trials or slower-than-expected adoption can adversely affect the company’s financial outlook and stock value, making such investments somewhat speculative.

• Fierce Competition: Mid cap pharma companies compete not only with their direct-size peers but also with large pharmaceutical giants and nimble small-cap firms, all vying for market share. This intense competition can impede growth and affect profitability, presenting a constant challenge for mid-sized companies.

• Market Sensitivity: Investments in mid cap pharma are highly sensitive to market dynamics and economic conditions. Changes in healthcare policies, insurance coverage, and consumer health trends can all influence the market success of the products these companies develop, adding an external layer of complexity to investment decisions.

Introduction to Mid Cap Pharma Stocks

Piramal Pharma Ltd

The Market Cap of Piramal Pharma Ltd is ₹19,750.47 crore. The stock has posted a 1-month return of 111.94% and a 1-year return of 2.86%. It is currently 11.24% below its 52-week high.

Piramal Pharma Limited, based in India, specializes in pharmaceuticals, distributing a diverse range of products domestically and internationally. The company operates through 17 global facilities, with its extensive distribution network reaching over 100 countries. Its business structure includes subsidiaries that enhance its global pharmaceutical influence.

The company’s subsidiaries, Piramal Pharma Solutions (PPS) and Piramal Critical Care (PCC), along with its consumer healthcare segment, form the core of its operations. PPS provides comprehensive development and manufacturing solutions across the drug lifecycle, catering to generic pharmaceutical companies. PCC focuses on complex hospital generics, including inhalation anesthetics and injectable therapies for pain and spasticity management, among other products.

Alembic Pharmaceuticals Ltd

The Market Cap of Alembic Pharmaceuticals Ltd is ₹18,868.09 crore. The stock has experienced a 1-month return of 69.10% and a 1-year return of 1.40%. It is currently 13.97% below its 52-week high.

Alembic Pharmaceuticals Limited, an India-based pharmaceutical company, engages in the manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). The company offers a broad spectrum of generic medications, predominantly for chronic segments across multiple therapeutic areas such as Dermatology, Anti-Infective, and Cardiology.

The company operates production facilities in Panelav, Karkhadi, and Jarod in Gujarat for International Generics, alongside research and development centers in Vadodara, Hyderabad, and New Jersey. Its APIs are produced at three plants in Gujarat, and a dedicated facility in Sikkim handles the production of its India Formulations. Alembic’s reach extends through subsidiaries including Alembic Pharmaceuticals Inc. and Alembic Global Holding SA.

Natco Pharma Ltd

The Market Cap of Natco Pharma Ltd is ₹17,823.22 crore. The stock has recorded a 1-month return of 59.88% and a 1-year return of 1.10%. It is currently 11.38% below its 52-week high.

Natco Pharma Limited is a vertically integrated pharmaceutical company based in India, focusing on research and development. Engaged in pharmaceuticals, it handles the research, development, manufacturing, and selling of bulk drugs and finished dosage formulations. The company markets its products in India, the United States, and other parts of the world.

Natco Pharma operates in two main segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment includes the production and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). Meanwhile, the agrochemicals segment concentrates on niche products such as pest management solutions, showcasing the company’s diverse capabilities in different areas of the chemical industry.

Suven Pharmaceuticals Ltd

The Market Cap of Suven Pharmaceuticals Ltd is ₹16,397.80 crore. The stock has achieved a 1-month return of 35.61% and a 1-year return of 1.48%. It is currently 19.23% below its 52-week high.

Suven Pharmaceuticals Limited is an India-based enterprise engaged in the development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (APIs), Specialty Chemicals, and formulated drugs. They provide these services under contract for global pharmaceutical, biotechnology, and chemical industries, operating primarily in the Pharmaceuticals Manufacturing and Services segment.

The company’s market is geographically diversified, with operations spanning India, the United States, Europe, and other regions. In India, Suven Pharmaceuticals sells bulk drugs, intermediates, and services, while in the United States, its focus is on intermediates and services. Europe sees the sale of bulk drugs and intermediates, and other countries receive a mix of all these offerings. Suven Pharma Inc. is a wholly-owned subsidiary of the company.

Concord Biotech Ltd

The Market Cap of Concord Biotech Ltd is ₹14,977.90 crore. The stock has posted a 1-month return of 51.86% and a 1-year return of -4.51%. It is currently 20.49% below its 52-week high.

Concord Biotech Limited, based in India, is a biopharma company focused on research and development. The company is involved in the manufacturing, marketing, and sales of pharmaceutical products, specializing in active pharmaceutical ingredients (API) produced through fermentation and semi-synthetic processes. It operates primarily in therapeutic areas like immunosuppressants, anti-bacterial, oncology, and anti-fungal treatments.

Their API lineup includes Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, and Vancomycin Hydrochloride, among others. Concord Biotech is also actively developing new APIs such as Polymyxin B, Fidaxomicin, and Doxorubicin. These efforts place the company at the forefront of innovation in critical care, immunology, nephrology, and transplant medicine, highlighting its role in addressing complex medical challenges.

AstraZeneca Pharma India Ltd

The Market Cap of AstraZeneca Pharma India Ltd is ₹14,397.50 crore. The stock has achieved a 1-month return of 74.46% and a 1-year return of 6.94%. It is currently 25.39% below its 52-week high.

AstraZeneca Pharma India Limited, an India-based biopharmaceutical company, focuses on several therapeutic areas including cardiovascular, renal, and metabolism (CVRM); oncology; and respiratory diseases. Operating within the Healthcare segment, the company is actively involved in the manufacturing, distribution, and marketing of pharmaceutical products.

The company’s CVRM business includes treatment options like Forxiga (Dapagliflozin) for heart failure and chronic kidney disease. In oncology, notable drug approvals include Imfinzi (Durvalumab) for Biliary Tract Carcinoma and Lynparza (Olaparib) for early breast cancer. Additionally, AstraZeneca offers a comprehensive portfolio of oral antidiabetic drugs, featuring SGLT2 inhibitors and DPP4 inhibitors, with brands like Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).

Eris Lifesciences Ltd

The Market Cap of Eris Lifesciences Ltd is ₹12,060.61 crore. The stock has posted a 1-month return of 39.24% and a 1-year return of 1.17%. It is currently 9.63% below its 52-week high.

Eris Lifesciences Limited, based in India, focuses on the manufacture and marketing of pharmaceutical products, with a manufacturing facility in Guwahati, Assam. The company specializes in a broad range of therapeutic areas such as oral diabetes care, cardiac care, pain management, gynecology, gastrointestinal treatments, the central nervous system, and vitamins, minerals, and nutrients.

The company’s extensive product line includes brands like Advog 0.2, Atorsave Gold 10, and Baga NT 100, among others, catering to various health needs. Eris Lifesciences operates several subsidiaries including Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited, enhancing its reach and capabilities within the pharmaceutical industry.

Jubilant Pharmova Ltd

The Market Cap of Jubilant Pharmova Ltd is ₹11,440.05 crore. The stock has experienced a 1-month return of 115.01% and a 1-year return of 4.47%. It is currently 2.57% below its 52-week high.

Jubilant Pharmova Limited is an integrated pharmaceutical company based in India, with operations spanning multiple sectors. The company is divided into three main segments: Pharmaceuticals, Contract Research and Development Services, and Proprietary Novel Drugs. Its Pharmaceuticals segment, through Jubilant Pharma Limited, specializes in the manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products, and contract manufacturing of sterile and non-sterile products.

The company operates six manufacturing facilities across India, the United States, and Canada, supporting a vast network of approximately 48 radio pharmacies in the U.S. The Contract Research and Development Services segment offers comprehensive drug discovery and development services, along with clinical data software and service solutions. Meanwhile, the Proprietary Novel Drugs segment focuses on developing biopharmaceuticals to meet critical needs in oncology and autoimmune diseases, aiming to significantly impact patient care in these challenging areas.

Best Mid Cap Pharma Stocks – FAQs

We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.